

Lian-Sheng Ma
President and Company Editor-in-Chief

Dear Dr Ma,

Re: Potential therapeutic targets from genetic and epigenetic approaches for asthma” to the World Journal of Translational Medicine.

Thank you very much for your inviting me to submit a revised manuscript that addressed the reviewers’ concerns. I was pleased to learn that the reviewers found that my manuscript was interesting and I appreciate the reviewers for the helpful suggestions and comments that have improved the paper and I have revised the manuscript and answered all of their concerns. Below are my point-by-point responses. The reviewer’s comment is given in bold, with my response following after. We have also submitted the revised paper with all changes marked in red, along with an unmarked draft.

Reviewer 1:

Nucleotide cysteine and adenine

Thanks for point out the mistake, I changed cysteine to cytosine.

D19(+) B lymphocyte

Thanks again, I replaced D19(+) with CD19(+)

Hyphenation of cytokine proteins

I have checked all the cytokine names and put hyphenation in them when the names present as proteins.

I checked the grammar and spelling of the manuscript thoroughly.

Reviewer 2:

Missing important references

I added the references in the manuscript.

GWASs on lung functions

I wrote addition words to explained GWASs on lung function in the manuscript.

Other important cytokine genes

My manuscript described the genes identified by GWASs or epigenetic studies. Of course candidate gene studied showed that many other cytokine genes significantly associated with asthma, but this manuscript is for GWASs or positional cloning genes. So far *IL17* and *IL25* had not been identified by GWASs or epigenetic approaches.

Traits

I change the “traits” to phenotypes in the table 1 and table 2.

Reviewer 3:

Thanks for reviewing the manuscript.

Yours sincerely,



Youming Zhang MB, MSc, DPhil
National Heart & Lung Institute
Imperial College London
Guy Scadding Building, Royal Brompton Campus
Dovehouse Street, London SW3 6LY